All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
CALGB 10403 long-term follow-up: Outcomes with intensive chemotherapy for AYA with ALL
Brexu-cel, a CD19 CAR T-cell therapy, is approved for the treatment of adults with R/R B-Results from the phase II CALGB 10403 study (NCT00558519) demonstrated the efficacy and feasibility of an intensive chemotherapy regimen in treatment-naïve AYA patients with ALL. The treatment schedule of CALGB 10403 was previously reported. During the European Hematology Association 2025 Congress, Wendy Stock presented 10-year follow-up data from the CALBG 10403 study.1 The study included 295 AYA patients; 76% had B-ALL and 24% had T-ALL. The median follow-up was 120.5 months.
|
Key learnings |
At 3 and 10 years the survival rates were 72.5% and 56%, respectively, with a median survival of 142 months. EFS and DFS rates were 44% and 49.3%, respectively. |
Relapses were reported in 102 patients; 19% occurred 3–5 years post CR and 6% occurred >5 years post CR. No relapses were reported after 3 years in patients with T-ALL. |
MRD-negative status was associated with longer OS (HR, 0.26; 95% CI, 0.10–0.69; p = 0.0037), while Ph-like (HR, 2.08; 95% CI, 1.19–3.65; p = 0.0089) and a BMI ≥30 (HR, 1.65; 95% CI, 1.11–2.47; p < 0.0001) were associated with worse OS. |
The landmark analysis demonstrated that relapse rates were lower in patients completing maintenance vs no maintenance therapy (HR, 0.35; 95% CI, 0.16–0.78; p = 0.01). |
The findings highlight the importance of early MRD eradication, completion of maintenance therapy, and long-term follow-up in pediatric patients with ALL. |
ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BMI, body mass index; B-ALL, B-cell acute lymphoblastic leukemia; CI, confidence interval; CR, complete remission; DFS, disease-free survival; EFS, event-free survival; HR, hazard ratio; MRD, measurable residual disease; OS, overall survival; Ph-like, Philadelphia chromosome-like; T-ALL, T-cell acute lymphoblastic leukemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
